NEW HAVEN, Conn., April 19, 2018 /PRNewswire/ -- Biohaven
Pharmaceutical Holding Company Ltd. (NYSE: BHVN) announced today
that it will hold an investor event concurrently with the 2018
American Academy of Neurology (AAN) Annual Meeting in Los Angeles, from 6:00
p.m. to 7:30 p.m. PT on Sunday, April 22, 2018. A live
webcast of the event may be accessed from the Events page under the
Investors section at http://www.biohavenpharma.com, with a replay
available for 60 days.
Biohaven recently announced successful achievement of both
co-primary endpoints in two pivotal Phase 3 clinical trials of
rimegepant, an oral CGRP receptor antagonist for the acute
treatment of migraine. In each trial, rimegepant met the
co-primary efficacy endpoints of pain freedom and freedom from most
bothersome symptom (MBS) at two hours post-dose. During the
event, a panel of migraine experts will discuss the potential
therapeutic benefits associated with the rimegepant Phase 3
clinical trial results.
Topic of Discussion:
Rimegepant Phase 3
Update: Single-Dose Durable Headache Relief and Return to
Function Endpoints. Pivotal trial presentation by Dr.
Richard Lipton followed by migraine
expert panel discussion.
Migraine Expert Panel:
- DAVID W. DODICK, MD;
Mayo Clinic Arizona: Professor, Department of
Neurology
- PETER GOADSBY, MD PhD;
King's College London: Professor of Neurology; and
Director, King's Clinical Research Facility, King's College
Hospital
- SUSAN HUTCHINSON, MD;
Orange County Migraine & Headache Center:
Director; President, Headache Cooperative of the Pacific
- RICHARD B. LIPTON, MD;
Albert Einstein College of Medicine: Edwin S.
Lowe Professor and Vice Chair of Neurology; Professor of
Epidemiology and Population Health; Director, Montefiore Headache
Center
Webcast
Biohaven will host a live video webcast of the
event starting at 9:00 p.m. ET
(6:00 p.m. PT). To access the video
webcast with slides, please visit the "Events" page in the
Investors section of the Company's website
at http://investors.biohavenpharma.com/events. A replay will
be available on the Company's website after the event.
Institutional investors and analysts may RSVP to attend in person
by contacting bkorb@troutgroup.com.
About Rimegepant
Rimegepant is Biohaven's orally-dosed
calcitonin gene-related peptide (CGRP) receptor antagonist, which
the Company is developing as an acute treatment for migraine.
Rimegepant represents a novel mechanism that targets the underlying
pathophysiology of migraine without causing vasoconstriction.
The efficacy and safety profile of rimegepant has now been
consistently established across three randomized controlled trials
to date: the two recently announced pivotal Phase 3 studies, and a
previously reported Phase 2b study.
The co-primary endpoints achieved in the Phase 3 trials are
consistent with regulatory guidance from the U.S. Food and Drug
Administration (FDA) and provide the basis for a planned submission
of a new drug application (NDA) to the FDA in 2019.
About Biohaven
Biohaven is a clinical-stage
biopharmaceutical company with a portfolio of innovative,
late-stage product candidates targeting neurological diseases,
including rare disorders. Biohaven has combined internal
development and research with intellectual property licensed from
companies and institutions including Bristol-Myers Squibb Company,
AstraZeneca AB, Yale University,
Catalent, ALS Biopharma LLC and Massachusetts General
Hospital. Currently, Biohaven's lead development programs
include multiple compounds across its CGRP receptor antagonist and
glutamate modulation platforms. More information about
Biohaven is available at www.biohavenpharma.com.
For further information, contact Dr. Vlad Coric, Chief Executive Officer, at
Vlad.Coric@biohavenharma.com
View original content with
multimedia:http://www.prnewswire.com/news-releases/biohaven-pharmaceuticals-announces-additional-phase-3-rimegepant-data-to-be-released-at-investor-event-held-concurrently-with-the-2018-american-academy-of-neurology-meeting-in-los-angeles-300632726.html
SOURCE Biohaven Pharmaceutical Holding Company Ltd.